Remove 2015 Remove FDA Remove Nursing Homes Remove Public Health
article thumbnail

Here are the major issues facing healthcare in 2021, according to PwC

Healthcare IT News - Telehealth

“Regulators, for their part, have tried to smooth the way for a pivot to virtual during the public health emergency. ” The FDA is hinting that some of these changes could be here to stay. For example, nursing homes were hit hard by the virus.

COVID-19 210
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – June

SQA

Ma rketing authorization holders (MAHs) can now register their Industry Single Point of Contact (i-SPOC) who will inform EMA about the supply and availability of critical medicines identified in the context of a ‘public health emergency’ or a ‘major event’. United States Food and Drug Administration (FDA) – Regulations and Guidances.

FDA 91
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Health Provider News

Hall Render

Here’s how to find quality care CEOs turn attention from recovery to growth ARKANSAS Statistics show many northern Arkansas locations considered maternity care deserts How broadband expansion is bolstering rural healthcare Arkansas leaders work to close gap between medical school graduates and in-state residencies Program in south Arkansas provides (..)

article thumbnail

Health Provider News

Hall Render

into cutting opioids in hospitals ISU and University of Utah partnership aims to combat Idaho’s mental health crisis Presbyterian-UnityPoint merger moves forward St. into cutting opioids in hospitals ISU and University of Utah partnership aims to combat Idaho’s mental health crisis Presbyterian-UnityPoint merger moves forward St.

article thumbnail

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

Since the FDA requires pre-approval of any warnings about off-label uses, preemption at some point should have been pre-ordained under the Mensing ( 2011+1 ) independence principle, but off-label use did not really figure in Zofran ’s analysis. The FDA’s five reviews of teratogenic risk all came to the same conclusion.

FDA 105